IL17A and rheumatoid arthritis: However, it cannot be completely ruled out that, in the future, targeting the IL-17 axis in RA at different levels (Th17 differentiation, receptors, signaling, etc.)will not provide better therapeutical results than the currently available monoclonal antibodies.